Connect Biopharma says rademikibart cuts COPD treatment failure rate 81% in Phase 2
Connect Biopharma reported preliminary topline results from a global Phase 2 trial of rademikibart in acute COPD flare-ups, cutting post-flare treatment failures versus placebo by 81% through Week 4 and planning to seek FDA alignment for a Phase 3 registrational add-on program.